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and modest therapeutic effects. Bone marrow (BM) -derived CD31þ cells are a promising cell source owing to their
high angiovasculogenic and paracrine activities.
OBJECTIVES This study sought to identify culture conditions that could augment the cell adhesion, angiogenic, and
anti-inﬂammatory activities of BM-derived CD31þ cells, and to determine whether these cultured CD31þ cells are
effective for cardiac and vascular repair.
METHODS CD31þ cells were isolated from human BM by magnetic-activated cell sorting and cultured for 10 days under
hematopoietic stem cell, mesenchymal stem cell, or endothelial cell culture conditions. These cells were characterized by
adhesion, angiogenesis, and inﬂammatory assays. The best of the cultured cells were implanted into myocardial
infarction (MI) and hindlimb ischemia (HLI) models to determine therapeutic effects and underlying mechanisms.
RESULTS The CD31þ cells cultured in endothelial cell medium (EC-CD31þ cells) showed the highest adhesion and
angiogenic activities and lowest inﬂammatory properties in vitro compared with uncultured or other cultured CD31þ cells.
When implanted into mouse MI or HLI models, EC-CD31þ cells improved cardiac function and repaired limb ischemia
to a greater extent than uncultured CD31þ cells. Histologically, injected EC-CD31þ cells exhibited higher retention,
neovascularization, and cardiomyocyte proliferation. Importantly, cell retention and endothelial transdifferentiation
was sustained up to 1 year.
CONCLUSIONS Short-term cultured EC-CD31þ cells have higher cell engraftment, vessel-formation, cardiomyocyte
proliferation, and anti-inﬂammatory potential, are highly effective for both cardiac and peripheral vascular repair, and
enhance survival of mice with heart failure. These cultured CD31þ cells may be a promising source for treating ischemic
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ABBR EV I A T I ON S
AND ACRONYMS
BM = bone marrow
DiI = 1,10-dioctadecyl-3,3,30 ,30-
tetramethylindocarbocyanine
perchlorate
EC = endothelial cell culture
conditions
EPC = endothelial progenitor
cell
FBS = fetal bovine serum
HC = hematopoietic stem cell
culture conditions
HLI = hindlimb ischemia
HUVEC = human umbilical vein
endothelial cell
MACS = magnetic activated
cell sorting
MC = MSC culture conditions
MI = myocardial infarction
MNC = mononuclear cell
MSC = mesenchymal stem cell
PBS = phosphate-buffered
saline
UC = uncultured cells
VWF = von Willebrand fac
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1682C ell therapy has emerged as a prom-ising new strategy for regeneratingdamaged ischemic tissue. Experi-
mental studies and pilot clinical trials with
various bone marrow (BM) cells, BM-
mononuclear cells (MNCs), early endothelial
progenitor cells (EPCs), or mesenchymal
stem cells (MSCs) have shown favorable ef-
fects on cardiac repair after myocardial in-
farction (MI) (1,2). Mechanistically, paracrine
actions are now known to be the main mecha-
nism underlying ischemic tissue repair (3–6).SEE PAGE 1695Recent meta-analyses of clinical trials
for cardiac cell therapy with BM cells
showed that left ventricular ejection frac-
tion improved only w4% (7). Interestingly,
selected populations such as CD34þ and
CD133þ (also known as prominin-1) cells did
not show signiﬁcant therapeutic advantages
over controls; rather, BM-MNCs and EPCs
were more effective than controls. These
results are not surprising given that para-
crine (rather than transdifferentiation) ef-
fects are the main mechanism for BM celltherapy, and further suggest that selection of stem or
progenitor cells may not be necessary when using
BM-derived cells (5,6). We recently reported that BM-
derived or peripheral blood-derived MNCs that ex-
press CD31 (also known as platelet endothelial cell
adhesion molecule-1) on the surface are a speciﬁc
cell population enriched with angiovasculogenic
properties (8,9). Although they include a small stem
cell population (<2%), the majority of CD31þ cells
are lineage-committed and constitute w25% of total
MNCs. We found that these cells are more effective
than BM-MNCs or BM-CD31- cells for repairing limb
ischemia.
However, collective data have shown that there is
still much room for improvement in therapeutic efﬁ-
cacy. Speciﬁcally, low cell retention in vivo is a major
limiting factor for cardiac cell therapy (10), and
vessel-forming capability also needs improvement.
Moreover, despite its importance, the need to reduce
inﬂammation is relatively underestimated and thus
underdeveloped (11).
Accordingly, this study was designed to improve
the function of newly identiﬁed CD31þ cells by cell
culture. Speciﬁcally, we sought to ﬁnd culture con-
ditions to induce higher adhesive, angiogenic, and
vasculogenic, but lower inﬂammatory, activities. We
also aimed to determine the therapeutic capability of
the cultured CD31þ cells in the treatment of ischemic
torheart and vascular disease. In addition to the well-
known paracrine or humoral effects of the cells, we
also addressed important and long-debated mecha-
nistic issues: endothelial transdifferentiation and
long-term fate of the implanted BM cells in tissues
(12,13). The present study demonstrated that CD31þ
cells cultured under speciﬁc endothelial cell media
exhibited the augmented cell biological charac-
teristics mentioned in the preceding text and are
effective for repairing experimental MI and limb
ischemia.
METHODS
An expanded Methods section is available in the
Online Appendix.
ISOLATION AND CULTIVATION OF CD31D CELLS.
Fresh human BM samples were purchased from Lonza
(Walkersville, Maryland). Isolation of CD31þ cells was
performed using magnetic activated cell sorting
(MACS) (Miltenyi Biotec, Auburn, California) with a
CD31 antibody, as we previously described (9). CD31þ
cells were plated at a density of 1  106 cells/cm2 on
plates in EBM-2 basal medium supplemented with
EGM-2 SingleQuots (Lonza) and 15% fetal bovine
serum (FBS) for the endothelial cell (EC) culture
conditions. In the MSC culture conditions (MC), cells
were grown in Dulbecco’s Modiﬁed Eagle’s Medium
with low glucose containing 15% FBS. In the he-
matopoietic stem cell culture conditions (HC), cells
were grown in Iscove’s Modiﬁed Dulbecco’s Medium
supplemented with 10% FBS, stem cell factor (50
ng/ml), thrombopoietin (20 ng/ml), and Fms-related
tyrosine kinase 3 ligand (20 ng/ml). All of the subse-
quent assays were performed with 10-day cultured
CD31þ cells.
CELL ADHESION ASSAY AND MATRIGEL NETWORK
FORMATION ASSAY. See the Online Appendix.
FLOW CYTOMETRY ANALYS IS . See the Online
Appendix.
QUANTITATIVE RT-PCR (QRT-PCR) ASSAY. See the
Online Appendix.
CELL TRANSPLANTATION INMYOCARDIAL INFARCTION
AND HINDLIMB ISCHEMIA MODELS. We performed MI
and cell transplantation as described previously
(6,14). See the Online Appendix.
HISTOLOGICAL ANALYSIS. Mice were sacriﬁced 2, 3
or 4 weeks or 1 year after cell transplantation. Hearts
and adductor muscles were harvested and ﬁxed for 4 h
in 4% paraformaldehyde and incubated overnight in
15% sucrose solution. The tissues were embedded in
OCT compound (Sakura Finetek USA, Torrance,
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FIGURE 1 In Vitro Cell Biological Characteristics of Cultured and Uncultured CD31þ Cells
(A)Morphologies of CD31þ cells cultured under hematopoietic stem cell (HC), mesenchymal stem cell (MC), and endothelial cell (EC) conditions at day 10. Bars¼ 200 mm.
(B) Growth curves of HC, MC, and EC. n ¼ 5 per group. **p < 0.01, *p < 0.05 vs. HC. (C) Endothelial and mesenchymal culture conditions induced CD31þ cells to express
endothelial proteins kinase insert domain receptor (KDR), CDH5, von Willebrand factor (VWF), and CD31 in culture. (D) Cell adhesion assays showed higher adhesion of EC
andMC to all tested extracellularmatrix proteins (ﬁbronectin [FN], vitronectin [VN], type I collagen [CL], laminin [LN]) comparedwith uncultured CD31þ cells (UC). n¼ 5per
group. Bars¼ 500 mm. (E) Tube formation potential. Tube lengths and the number of branching points were measured 24 h after seeding of cultured or uncultured CD31þ
cells in Matrigel coated plates. n¼ 5 per group. Bars¼ 500 mm. (F) Tube formation by coculture with human umbilical vein endothelial cells (HUVEC). Tube lengths and the
number of branching points were measured 12 h after seeding of 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate–labeled cultured or uncultured CD31þ
cells in Matrigel-coated plates. n ¼ 5 per group. Bars ¼ 500 mm. (G) Tube formation assay using HUVEC only. Tube lengths and the number of branching points were
measured 5 h after seeding of HUVEC in Matrigel-coated plates. n ¼ 5 per group. **p < 0.01. Bars ¼ 200 mm. (D-F) **p < 0.01 vs. UC, *p < 0.05 vs. UC. AD ¼ adherent;
HPF ¼ high-powered ﬁeld.
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FIGURE 2 Flow Cytometric Analyses of Cultured and Uncultured CD31þ Cells
(A) Representative histograms of ﬂow cytometry data. The CD31þ cells cultured under the
3 conditions for 10 days were labeled with phycoerythrin-conjugated (red spectra) or
ﬂuorescein isothiocyanate–conjugated (green spectra) antibodies and analyzed by ﬂow
cytometry for hematopoietic and endothelial markers. (B) Quantitative analyses (n ¼ 4
each). ENG ¼ endoglin; ITGAM ¼ integrin alpha M; KIT ¼ proto-oncogene c-Kit;
MCAM ¼ melanoma cell adhesion molecule; PROM1 ¼ prominin-1; PTPRC ¼ protein
tyrosine phosphatase receptor type C; TEK ¼ tyrosine kinase, endothelial; THBD ¼
thrombomodulin; other abbreviations as in Figure 1.
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1684California), snap-frozen in liquid nitrogen, and
sectioned at 10 - 20 mm thickness as described
previously by our laboratory. For quantiﬁcation of
capillary density, 4 randomly selected frozen sectionsof the peri-infarct border area and ischemic tissue from
the adductor muscles from each group were stained
with primary biotinylated ILB4 (1:250, Vector Labora-
tory Inc., Burlingame, California), secondary strepta-
vidin Alexaﬂuor 488 (1:400, Invitrogen, Carlsbad,
California) and Cy2 (1:400, Jackson ImmunoResearch,
West Grove, Pennsylvania). Five ﬁelds from 4 tissue
sections were randomly selected, and the number of
capillaries was counted in each ﬁeld. To identify
cardiomyocytes, anti-a sarcomeric actinin antibody
(Sigma) was used. Ki-67 expression was evaluated
with a rabbit monoclonal anti-Ki-67 antibody
(Thermo scientiﬁc, Hudson, New Hampshire) as
described previously (1). TdT-mediated dUTP nick-
end labeling (TUNEL) assay was performed using a
ﬂuorescein in situ cell death detection kit (Roche
Molecular Biochemical, Indianapolis) as described
previously (1). To identify human male CD31þ cells
injected into female recipients, ﬂuorescence in situ
hybridization (FISH) was performed with a Cy3-con-
jugated (Cambio, Cambridge, United Kingdom) hu-
man Y chromosome probe (3). 4’,6-diamidino-2-
phenylindole (DAPI) was used to identify nuclei. The
ﬁbrosis area was examined by the computer software
Image-Pro Plus after Masson’s trichrome staining.
Pictures were taken using ﬂuorescence inverted mi-
croscopy or confocal microscopy.
FLOW CYTOMETRY ANALYSIS OF DIGESTED TISSUES.
To identify the engraftment and endothelial trans-
differentiation of tissue-injected CD31þ Cells, we
performed ﬂow cytometric analysis as described
previously (2,3). Animals were systemically perfused
with Alexa Fluor 647-conjugated ILB4 (50 mg for 10
min, Molecular Probes) before sacriﬁce. In brief, Dil-
labeled CD31þ cells were injected into heart or
ischemic hindlimb of nude mice. At predetermined
time points, the ischemic hindlimb or heart tissues
were harvested, minced, and then digested at
37C for 45–60 min with an enzyme cocktail
(Collagenase A, Elastase, and DNase I, Roche
Applied Science, Indianapolis, Indiana). Single cell
suspensions were prepared by ﬁltering through a
30-mm strainer. Labeled cell populations were
measured by a LSRII ﬂow cytometer (BD Biosci-
ence). Flow cytometry data were analyzed with
FlowJo software (Tree Star, Ashland, Oregon). Flow
cytometric analysis was performed using a variety
of controls including unstained samples and isotype
antibodies.
STATISTICAL ANALYSIS. All data are shown as
mean  SEM. Statistical analyses were performed
with Student t test for comparisons between two
groups and ANOVA with the Turkey test for multiple
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FIGURE 3 Expression of Angiogenic, Integrin, and Inﬂammatory Factors
Quantitative reverse transcriptase polymerase chain reaction was performed to measure the level of gene expression from cultured and
uncultured CD31þ cells. Various angiogenic (A), cell adhesion (integrin) (B), proinﬂammatory (C), and anti-inﬂammatory (D) factors were
up-regulated or down-regulated in the cultured groups compared with the uncultured group (n ¼ 4 each; *p < 0.05; **p < 0.01). Individual
values were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (†p < 0.05, HC vs. EC; ‡p < 0.01, HC vs. EC; §p < 0.05, EC
vs. MC; ¶p < 0.01, EC vs. MC; kp < 0.01, MC vs. HC). AKT1 ¼ Ak strain transforming oncogene; ANGPT1/2 ¼ angiopoietin 1/2; CCL2 ¼
chemokine (C-C motif) ligand 2; FGF2 ¼ basic ﬁbroblast growth factor; HGF ¼ hepatocyte growth factor; IFNG ¼ interferon gamma; IGF1 ¼
insulin-like growth factor-1; IL(n) ¼ interleukin (n); IL1R1 ¼ interleukin-1 receptor, type-1; ITGA5/6 ¼ integrin alpha-5/-6; ITGB1/2 ¼ integrin
beta-1/-2; LIF ¼ leukemia inhibitory factor; MMP9 ¼ matrix metallopeptidase-9; PDGFB ¼ platelet-derived growth factor beta; PlGF ¼
placental growth factor; TGFB1 ¼ transforming growth factor beta-1; TNF ¼ tumor necrosis factor; TNFRSF1A ¼ tumor necrosis factor
receptor 1A; VEGFA ¼ vascular endothelial growth factor A; other abbreviations as in Figure 1.
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1685group comparisons by using SPSS version 11.0.
p < 0.05 was considered to denote statistical signiﬁ-
cance. The incidence of limb loss was analyzed using
the chi-square test. Where heterogeneity of variance
was identiﬁed, results were conﬁrmed with the non-
parametric Mann-Whitney U test.RESULTS
CELL BIOLOGICAL CHARACTERISTICS OF CD31D
CELLS CULTURED UNDER VARIOUS CONDITIONS.
To investigate the adhesive, vasculogenic, and
proliferative capacity of CD31þ cells, we isolated
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FIGURE 3 Continued
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1686CD31þ cells from human BM-MNCs using MACS.
The purity of CD31þ cells was 97.6  1.2%. First, we
compared the expansion proﬁle of CD31þ cells. The
same number of CD31þ cells was cultivated under 3
culture conditions, MC, EC, and HC. After 7 days
of culture, nonadherent cells were removed in MC
and EC. The adherent cells showed heterogeneous
morphology, including round and spindle-shaped
cells (Figure 1A). MC-CD31þ and EC-CD31þ cells
grew quickly from day 7 to 25, showing higher
proliferation properties than the HC-CD31þ cells
(Figure 1B). CD31þ cells in EC (EC-CD31þ) for 10 days
expressed endothelial cell proteins von Willebrand
factor (VWF), kinase insert domain receptor (KDR),
CDH5 (VE-cadherin), and CD31, but MC-CD31þ and
HC-CD31þ did not express CDH5 or VWF by immu-
nocytochemistry (Figure 1C).
As adhesion capacity is an important indicator of
cell engraftment and survival in vivo, we performed
an adhesion assay. The number of cells adherent to
extracellular matrix proteins ﬁbronectin, vitro-
nectin, collagen I, and laminin was signiﬁcantly
higher in the MC and EC groups than the uncultured
CD31þ cells (UC) (all p < 0.01) (Figure 1D). We per-
formed Matrigel tube formation assays with cultured
or uncultured CD31þ cells alone or cocultured with
human umbilical vein endothelial cells (HUVECs).
Without coculture with HUVECs, only EC-CD31þ
cells showed meaningful tube formation. With
coculture with HUVECs, all cultured CD31þ cells
showed higher branching points and tube lengths
compared with the UC (Figures 1E and 1F). When
HUVECs were cultured alone on Matrigel underthese conditions, the HUVECS cultured under EC
conditions (EC-HUVECs) exhibited higher branching
points and tube lengths compared with the HC-
HUVECs and MC-HUVECs (Figure 1G). These data
indicate that CD31þ cells cultured in EC have the
highest adhesion and independent tube-forming
capability.
SURFACE PROTEIN EXPRESSION OF CULTURED AND
UNCULTURED CD31D CELLS. To characterize cultured
CD31þ cells, we performed ﬂow cytometry analyses.
Regardless of cell culture, CD31þ cells maintained
expression of the pan-hematopoietic marker PTPRC
(protein tyrosine phosphatase, receptor type, C, also
known as CD45) as well as CD31 (Figure 2). Cells
expressing lineage-committed markers CD3 (T cell)
or CD19 (B cell) were decreased during culture. Cells
exhibiting stem cell markers CD34, PROM1 (CD133),
and KIT (proto-oncogene c-Kit, or CD117) were
maintained in HC but generally decreased in the
other conditions. Under EC, the cell populations
expressing hematopoietic-endothelial markers KDR
and TEK (tyrosine kinase, endothelial, or TIE2),
monocyte-macrophage markers ITGAM (integrin
alpha M, or CD11b) and CD14, and a dendritic cell
marker, THBD (thrombomodulin, or CD141), were
signiﬁcantly increased, whereas those expressing
ENG (endoglin, or CD105) and MCAM (melanoma
cell adhesion molecule, or CD146) were not signiﬁ-
cantly changed. Although MC cells showed similar
trends to EC with less prominent increases in TEK,
KDR, THBD, ITGAM, and CD14, HC cells did not
change or reduced their expression. These data
suggest that CD31þ cells cultured under 3 different
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FIGURE 4 Endothelial Cell Transplantation Is Effective for Infarct Repair
(A) Representative M-mode echocardiograms. (B) Left ventricular end-diastolic
dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) were lowest in
the endothelial cell (EC) group. Left ventricular fractional shortening (LVFS) was better
in EC-injected hearts compared with uncultured cell (UC)-injected or phosphate-
buffered saline (PBS)-injected hearts at 3 weeks after myocardial infarction (n ¼ 7 each;
*p < 0.05). (C) Representative cross-sectional images of hearts stained with Masson’s
trichrome at 4 weeks after cell transplantation. The blue color represents ﬁbrosis. (D)
EC transplantation offered the highest reduction in ﬁbrosis area (n ¼ 7; *p < 0.05;
**p < 0.01).
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1687conditions have distinct characteristics and the EC
conditions in general induced the highest
endothelial-monocytic phenotype shift of CD31þ
cells.
EXPRESSION OF ANGIOGENIC, INTEGRIN, AND
INFLAMMATORY GENES. To measure mRNA expres-
sion, we conducted qRT-PCR. Expression of angio-
genic factors such as basic ﬁbroblast growth factor
(FGF2), hepatocyte growth factor (HGF), platelet-
derived growth factor beta (PDGFB), placental
growth factor (PlGF), and matrix metallopeptidase
(MMP)-9 were signiﬁcantly increased in all culture
conditions compared with the UC (Figure 3A). Of note,
chemokine (C-C motif) ligand 2 (CCL2) and inter-
leukin (IL)-8, which play important roles in arterio-
genesis, were also increased in all conditions
(Figure 3A). Expression of cell survival factors insulin-
like growth factor (IGF)-1 and Ak strain transforming
oncogene (AKT1) were generally increased after
culture. We also measured expression of integrin
beta-1 (ITGB1), integrin beta-2 (ITGB2), integrin
alpha-5 (ITGA5), and integrin alpha-6 (ITGA6), as
these molecules mediate cell-to-cell and cell-to-
extracellular matrix interactions, regulating adhe-
sion and angiogenesis (15,16). These integrin levels
were increased in all culture conditions and were
particularly higher in EC compared with UC
(Figure 3B). Expression of representative inﬂamma-
tory genes interleukin-1 beta (IL1B), IL6, and inter-
feron gamma (IFNG) was decreased in all conditions
compared with UC (Figure 3C). However, anti-
inﬂammatory factors IL10 (17), transforming growth
factor beta-1 (TGFB1) (18), interleukin 1 receptor, type 1
(IL1R1), tumor necrosis factor receptor 1A (TNFRSF1A),
and leukemia inhibitory factor (LIF) were 3-fold to
30-fold increased in the cultured CD31þ cells, notably
in EC (Figure 3D). Collectively, these ﬁndings indicate
that cultured CD31þ cells, particularly in EC, are
enriched with vessel-formation, cell-survival, and
anti-inﬂammatory factors.
FAVORABLE EFFECTS OF CULTURED CD31D CELLS
ON REPAIR OF CARDIAC AND HINDLIMB ISCHEMIA.
We next investigated the therapeutic effects of
cultured CD31þ cells on infarct repair. On the basis of
the in vitro data, we selected EC-CD31þ cells cultured
for 10 days and compared the effects to UC-CD31þ
cells and phosphate-buffered saline (PBS). After in-
duction of MI in nude mice, we injected 1  106
cells or the same volume of PBS directly into the
peri-infarct area. Echocardiography at 3 weeks after
cell transplantation demonstrated that left ventricu-
lar end-diastolic dimension and left ventricular end-
systolic dimension were the lowest in the EC group,and left ventricular fractional shortening was the
highest in the EC group followed by the UC and PBS
groups (Figures 4A and 4B). Compared with the PBS
group, both UC and EC groups showed signiﬁcantly
lower circumferential ﬁbrosis area examined at 4
weeks, with the smallest in the EC group (Figures 4C
and 4D). These results indicate that intracardiac
implantation of uncultured or cultured CD31þ cells
can attenuate cardiac dysfunction and remodeling,
with the EC-CD31þ cells having higher potency.
We next evaluated the therapeutic potential of
cultured CD31þ cells in HLI. After creating HLI in
nude mice, we injected 10-day cultured EC-CD31þ
cells, MC-CD31þ cells, or HC-CD31þ cells, UC-CD31þ
cells, or PBS into the ischemic hindlimbs (1  106 cells
per mouse). Laser Doppler perfusion imaging was
performed weekly to monitor the ischemic hindlimb’s
PBS
EC
UC
*
**
ns
MergedKi-67B
**
**
*
PBS
EC
UC
PBS
EC
UC
*
**
**
ILB4 Merged
MergedTUNEL
A
C
FIGURE 5 Endothelial Cell Transplantation Increased Neovascularization and Cardiomyocyte Proliferation and Protection, and Suppressed Inﬂammation In Vivo
(A) Isolectin B4 (ILB4) staining for the peri-infarct regions and quantitative analysis of capillary density (n ¼ 7 each; *p < 0.05, **p < 0.01). Bars ¼ 50 mm; sarcomeric
a-actinin staining (red). (B) Double immunohistochemistry with Ki-67 and sarcomeric a-actinin antibodies for the peri-infarct regions and quantitative analysis (n ¼ 7
each; *p < 0.05, **p < 0.01). Arrows indicate Ki-67–positive cardiomyocytes. Bars ¼ 20 mm. (C) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay with sarcomeric a-actinin staining for the peri-infarct regions and quantitative analysis (n ¼ 7 each; *p < 0.05, **p < 0.01). Bars ¼ 50 mm. (D-E) Quantitative
reverse transcriptase polymerase chain reaction analyses with peri-infarct tissues injected with PBS, UC, or EC. EC transplantation showed the highest expression of most
angiogenic factors (D) and anti-inﬂammatory factors (E) and the lowest expression of pro-inﬂammatory factors (F). Data are presented as fold differences from the PBS
group (n ¼ 5 each; *p < 0.05; **p < 0.01). Abbreviations as in Figures 1, 3, and 4.
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1688blood ﬂow. Laser Doppler perfusion imaging analysis
revealed a greater recovery of blood perfusion in the
EC group compared with each of the other 4 groups
(Online Figures 1A and 1B). Although limb loss was
frequently observed in the PBS control group, the EC
group showed a signiﬁcantly lower limb loss score than
the PBS, UC, or MC groups (Online Figures 1C and 1D).
Capillary density in the hindlimb muscle was signiﬁ-
cantly higher in the EC group compared with that of
the PBS, UC, and MC groups (p < 0.01 vs. PBS; p < 0.05
vs. UC or MC) (Online Figure 2A). These resultssuggest that among all the groups, EC-CD31þ cells
have better therapeutic potential for ischemic limb
recovery.
NEOVASCULARIZATION, CARDIAC PROLIFERATIVE AND
PROTECTIVE EFFECTS, AND ANTI-INFLAMMATORY
EFFECTS OF CULTURED CD31D CELLS. In the MI
model, the capillary density at the peri-infarct area at
4 weeks was also highest in the EC group, followed
by the UC and PBS groups (Figure 5A). We deter-
mined cardiomyocyte proliferation and apoptosis
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1689with cardiac samples harvested at 2 weeks using
double staining for Ki67 and sarcomeric a-actinin
or double staining for terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and
sarcomeric a-actinin, respectively. The EC group
showed signiﬁcantly higher numbers of Ki67þ car-
diomyocytes compared with the UC and PBS groups
(Figure 5B). Apoptotic cardiomyocytes at the peri-
infarct area measured by TUNEL assay were lowest
in the EC group, followed by the UC and PBS groups
(Figure 5C). These results suggest that EC-CD31þ
cells have robust cardiac proliferative and protec-
tive effects.
To determine other humoral effects of cell trans-
plantation on ischemic hearts, MI mice were sacri-
ﬁced and cardiac tissues were collected at 1 week.
The expression levels of vascular endothelial growth
factor A (VEGFA), angiopoietin-1 (ANGPT1), PDGFB,
IGF1, and CD31 were signiﬁcantly increased in the
EC group compared with the PBS or UC groups
(Figure 5D). FGF2 was the only factor more highly
expressed in the UC group compared with the EC or
PBS groups. Compared with the other groups, the
expression of anti-inﬂammatory factors IL10 and
TGFB1 was signiﬁcantly higher and that of the
proinﬂammatory factors IL1B and tumor necrosis
factor (TNF) was lower in the EC group (Figures 5E
and 5F). These data indicate that direct cardiac in-
jection of EC-CD31þ cells augmented multiple bio-
logical factors associated with vascularization and
anti-inﬂammation and reduced proinﬂammatory
factors.CULTUREDCD31DCELLS SHOWEDHIGHER ENGRAFTMENT
AND ENDOTHELIAL TRANSDIFFERENTIATION POTENTIAL.
We determined engraftment and transdifferentiation
potential in tissue samples harvested from the heart
and the limb muscles at 4 weeks. Histologic analyses
demonstrated that injected 1,10-dioctadecyl-3,3,30,30-
tetramethylindocarbocyanine perchlorate (DiI)-labeled
EC-CD31þ cells or UC-CD31þ cells were engrafted in both
tissues and mainly localized in the pericytic or peri-
vascular areas of the hearts (Figure 6A) and limb muscles
(Online Figure 3A). We also found that a portion of CD31þ
cells was incorporated into vessels and exhibited endo-
thelial marker isolectin B4 (ILB4) (Figure 6B, Online
Figure 3B). By histomorphometric analyses, the
numbers of engrafted cells (DiIþ cells) and endothe-
lially transdifferentiated cells (DiIþ, ILB4þ cells) were
signiﬁcantly higher in the EC group compared with the
UC group (Figure 6B, Online Figure 3B, right panels).
To more precisely quantify the rate of engraftment
and transdifferentiation of CD31þ cells, we conducted
ﬂow cytometric analysis on enzymatically digested
hearts after systemic injection of ILB4 as described (8).
This analysis again demonstrated that the EC group
exhibited w2-fold higher engraftment and w3-fold
higher endothelial transdifferentiation rates compared
with the UC group (Figures 6C and 6D). Similar results
were found in the histologic and ﬂow cytometric ana-
lyses of the HLI model (Online Figures 3C and 3D).
Collectively, these ﬁndings suggest that, compared with
uncultured CD31þ cells, EC-CD31þ cells have superior
potency for engraftment and endothelial trans-
differentiation.
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FIGURE 6 Cultured CD31þ Cells Showed Higher Engraftment and Endothelial Transdifferentiation Capacity in the Ischemic Heart
(A-B) Histological analyses of engrafted cells in the heart sections 4 weeks after EC or UC (1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate [DiI]-
labeled, red ﬂuorescence) injection. (A) EC had higher retention compared with UC. n ¼ 5 each. *p < 0.05. (B) Confocal microscopic examination demonstrated that
injected UC-CD31þ cells (upper panel) or EC-CD31þ cells (lower panel) were colocalized with ILB4 (white arrows) using 3-dimensional z-stacked orthogonal and
multipanel images. Arrows indicate colocalized cells and arrowheads indicate engrafted cells in the perivascular areas. Quantiﬁcations of DiI and ILB4-double
positive cells are shown on the right. n ¼ 5 each. *p < 0.05. (C-D) Flow cytometry analyses of digested cardiac tissues at 4 weeks. (C) Higher engraftment of EC
compared with UC occurred, n ¼ 5 each. *p < 0.05. (D) Quantiﬁcation of DiI and ILB4 double-positive cells showing a higher rate of endothelial transdifferentiation
in EC compared with UC-injected hearts. n ¼ 5 each. *p < 0.05. P1 gating represents ILB4þ fraction and P2 gating double-positive population for DiI and ILB4.
DAPI ¼ 40,6-diamidino-2-phenylindole; SSC ¼ side scatter. Abbreviations as in Figures 1 and 5.
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1690LONG-TERM ENGRAFTMENT AND ENDOTHELIAL
TRANSDIFFERENTIATION POTENTIAL OF CD31D
CELLS. We further quantiﬁed the long-term en-
graftment and endothelial transdifferentiation of
cultured CD31þ cells using tissues harvested 1 year
after cell transplantation. Contrary to the prevailing
notion that injected BM cells in tissues survive
only for a short term, histological analyses of
the heart and hindlimb muscles showed engrafted
CD31þ cells, as well as those expressing ILB4,
within the vascular structure (Figure 7A,
Online Figure 4A). Quantitative analyses with ﬂowcytometry after perfusion of ILB4 and enzymatic
digestion of heart and hindlimb muscle revealed
an w0.6% engraftment rate (DiIþ cells per total
cells) (Figure 7B) and w2.1% endothelially trans-
differentiated cells (DiIþILB4þ cells) among total
endothelial cells in heart tissues (Figure 7C), and
w0.4% engrafted cells (Online Figure 4B) and w3.7%
endothelially transdifferentiated cells in hindlimb
muscle (Online Figure 4C). We also conﬁrmed these
results with ﬂuorescence in situ hybridization. Y
chromosome signals derived from human CD31þ cells
were detected in nuclei of endothelial cells as well as
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FIGURE 7 Engraftment and Endothelial Transdifferentiation Capacity at 1 Year in the Ischemic Heart
(A) Cardiac tissues were harvested at 1 year after injection with DiI-labeled EC. Confocal microscopic examination showed perivascular
localization of injected EC as well as colocalized DiI-labeled EC (red) with ILB4-stained endothelial cells (green) in vessels in z-stacked
orthogonal and multipanel images. Blue, DAPI. (B) Flow cytometry analysis showing presence of DiI-labeled EC in hearts at 1 year after EC
injection (n ¼ 5 each). Heart tissues were harvested at 1 year and digested with an enzyme cocktail. (C) Flow cytometry analysis demonstrating
DiI and ILB4 double-positive cells showing endothelial transdifferentiation of injected DiI-labeled EC. P1 gating represents the ILB4þ fraction
and P2 gating represents the cell population double positive for both DiI and ILB4. Abbreviations as in Figures 1, 5, and 6.
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1691in other myocardial cells (Online Figures 5A and 5B).
These ﬁndings conﬁrmed the long-term survival and
endothelial cell transdifferentiation capabilities of
EC-CD31þ cells in vivo.
DISCUSSION
To improve cardiovascular cell therapy, continuous
efforts have been made to identify more potent
cells and to improve their function. This studydemonstrated that speciﬁc culture conditions enhance
the tissue reparative function of BM-derived hemato-
poietic CD31þ cells. In modiﬁed endothelial culture
conditions, CD31þ cells expressed the highest levels
of adhesion, pro-angiogenic, and anti-inﬂammatory
factors, and the lowest levels of inﬂammatory factors
compared with uncultured CD31þ cells or CD31þ cells
that were cultured under other conditions. These EC-
CD31þ cells, when implanted in vivo, showed robust
neovascularization and cell retention, and induced
CENTRAL ILLUSTRATION Enhanced Therapeutic Effects of BM-Derived CD31þ Cells
for Cardiac and Vascular Repair
The bone marrow–derived CD31þ cells cultured in endothelial cell medium (EC-
CD31þ cells) showed higher adhesion and angiogenic activities and low inﬂamma-
tory properties in vitro compared with uncultured or other cultured CD31þ cells.
When implanted into mouse myocardial infarction (MI) or hindlimb ischemia (HLI)
models, EC-CD31þ cells improved cardiac function and repaired limb ischemia to a
greater extent than uncultured CD31þ cells. Mechanistically, injected EC-CD31þ cells
induced higher retention, neovascularization, cardiac protection, and cardiomyocyte
proliferation, and lower inﬂammatory reactions.
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1692cardiac and ischemic limb repair to a greater extent
than uncultured CD31þ cells. Of note, mice receiving
EC-CD31þ cells after MI had a signiﬁcantly higher
7-month survival rate, implying additional clinical
beneﬁts of EC-CD31þ cell therapy for heart
failure. Although low, cell survival and endothelial
transdifferentiation capacity was conﬁrmed for up to
a year. This is the ﬁrst report to demonstrate such
long-term engraftment of any injected BM cells and
maintenance of the endothelially transdifferentiated
phenotype.
The original goals of culturing CD31þ cells were
to enhance their adhesion and angiogenic-paracrine
capacities. As expected, cultures in the EC condi-
tions augmented both activities in CD31þ cells. The
most notably increased factors were integrins,
which are cell adhesion receptors that interact with
extracellular matrices (19) and play a critical role in
cell adhesion, cell survival, endothelial cell migra-
tion and proliferation, and matrix metalloproteinase
activation. Integrins also interact with receptors for
2 main angiogenic factors, VEGF and FGF, to facil-
itate angiogenesis (16,20). Under EC conditions,
multiple angiogenic, arteriogenic, antiapoptotic,
and chemoattractant factors essential for vesselformation, cell survival, and tissue repair were
signiﬁcantly increased. These higher cell adhesion
and angiogenic activities in the EC-CD31þ cells
synergistically functioned to enhance cell survival,
neovascularization, and tissue regeneration in vivo.
They further increased cardiomyocyte proliferation
and reduced cardiomyocyte apoptosis. It is also
likely that the enriched paracrine factors, such
as IGF1 and HGF, could have activated resident
cardiac stem cells to induce myocardial regenera-
tion (21,22).
To our surprise, key proinﬂammatory cytokines
were suppressed and anti-inﬂammatory cytokines
were increased in the EC-CD31þ cells. These anti-
inﬂammatory properties are beneﬁcial for acute car-
diovascular tissue repair. After MI, inﬂammatory cells
inﬁltrate the ischemic heart tissue and secrete in-
ﬂammatory cytokines (23). Excessive or prolonged
inﬂammation in MI leads to cardiac dysfunction.
Studies also reported that unselected BM cell trans-
plantation caused calciﬁcation in hearts or ulceration
in limbs, which are associated with proinﬂammatory
activities of the injected cells (24,25). The EC-CD31þ
cells highly expressed anti-inﬂammatory factors
IL10 and TGFB1. IL10 is a well-known anti-inﬂam-
matory cytokine, a representative suppressor of
proinﬂammatory mediators, and has auspicious ef-
fects on cardiac repair (17). TGFB1 is another major
regulator controlling inﬂammation (18). Anti-
inﬂammation factors, such as IL1R1, TNFRSF1A, and
LIF, were also more highly expressed compared with
uncultured CD31þ cells (26,27).
We also observed improved cell engraftment in
the cultured CD31þ cells. At 4 weeks, there were
twice as many surviving EC-CD31þ cells as uncul-
tured CD31þ cells in both the MI and HLI models.
Given our prior studies showing 4.5 times higher
survival of uncultured CD31þ cells compared with
uncultured CD31- cells (8,9), EC-CD31þ cells have
more than 9 times higher cell engraftment potential
than the uncultured CD31- cells that comprise 75%
of the most commonly used MNCs for cell therapy.
Another important observation is the endothelial
transdifferentiation or vasculogenic potential of EC-
CD31þ cells. Although the transdifferentiation po-
tential of BM-derived cells has been under debate,
this study showed that EC-CD31þ cells retained even
higher endothelial transdifferentiation potential
than uncultured CD31þ cells (8,9). Compared with
uncultured CD31þ cells, EC-CD31þ cells had a 3-fold
(MI model) to 4-fold (HLI model) higher trans-
differentiation rate at 1 month. The hindlimb
muscle showed a substantially higher rate of trans-
differentiated ECs than myocardium (8% vs. 1.5%).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Cell therapy
holds promise as a treatment strategy to regenerate damaged
ischemic tissue, but low engraftment of administered cells and
modest therapeutic effects are important limitations. Short-term
cultured bone marrow–derived CD31þ cells yielded higher cell
engraftment, vessel formation, cardiomyocyte proliferation, and
anti-inﬂammatory effects in mouse models of ischemic cardiac
and vascular diseases.
TRANSLATIONAL OUTLOOK: The clinical efﬁcacy and safety
of bone marrow–derived CD31þ cells for tissue salvage and re-
covery in patients with ischemic limbs and for restoration of
ventricular function and survival after myocardial infarction
should be investigated in future studies.
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were extended up to a year. To date, no studies
have addressed the long-term fate of direct tissue-
injected BM cells in vivo. Histologic examination
of >1,000 sections and ﬂow cytometry analyses
demonstrated durable survival and endothelial
transdifferentiation of EC-CD31þ cells in both heart
and limb muscle at 1 year.
Although EC-CD31þ cells were the most effective
for ischemic limb recovery, CD31þ cells cultured
under other conditions also were more effective
than control cells. Compared with uncultured CD31þ
cells, all cultured CD31þ cells displayed increased
angiogenic and decreased inﬂammatory properties.
However, EC-CD31þ or HC-CD31þ cells have higher
proangiogenic factors and activities than MC-CD31þ
cells. The proinﬂammatory and anti-inﬂammatory
proﬁles are similar between HC-CD31þ cells and
MC-CD31þ cells, but are more favorable in EC-CD31þ
cells. However, it remains to be determined
whether these cultured cells have different effects
on the repair of acute MI according to the culture
conditions.
STUDY LIMITATIONS. Although meta-analyses demon-
strated relatively small effects in improvement of
ejection fraction overall for BM cell therapy (7), recent
clinical trials with MSCs for ischemic cardiomyopathy
demonstrated various beneﬁcial effects, including
enhanced heart failure score and reduction of scar size
and cardiac volume indices (28,29). The current study
also attempted long-term follow-up of cardiac func-
tion for a year, but all animals in the UC and PBS
groups died by 7 months, whereas those treated with
the EC-CD31þ cell group all survived. Together, these
studies suggested that adult cell therapy remains a
viable therapeutic option, and various parameters
other than left ventricular ejection fraction areneeded to appropriately address the advantages of
clinical cell therapy.
CONCLUSIONS
We demonstrated for the ﬁrst time that culture-
expanded CD31þ cells induced enhanced adhesion,
vessel formation, cardiomyocyte proliferation, and
anti-inﬂammatory effects, and are effective for
repairing cardiovascular damage (Central Illustration).
These cells may be a novel and advanced thera-
peutic option for treating ischemic cardiovascular
disease.
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and an expanded Methods section, please see
the online version of this article.
